Overview
- Eli Lilly will build a $3 billion oral-medicines facility in Katwijk’s Leiden Bio Science Park, featuring dock-to-dock automation, digital manufacturing systems, process monitoring, and spray-dried technologies.
- The site is slated to produce orforglipron, Lilly’s oral GLP-1 candidate, alongside other oral solid drugs in cardiometabolic health, neuroscience, oncology, and immunology.
- Lilly says it plans a global regulatory submission for orforglipron in obesity by the end of 2025, with a separate type 2 diabetes filing expected in 2026 after additional data.
- Shares gained roughly 3.6% to about $894 in Monday trading as analysts reiterated broadly positive views, including Cantor Fitzgerald’s late-October target hike to $985, though Berenberg recently moved to Hold.
- Lilly continues to navigate pricing and access questions, with IRA-related negotiations in focus and reported talks about offering discounted medicines on the TrumpRx website.